Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators..

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

2.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

3.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators..

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

4.

Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).

Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J.

Am J Cardiol. 2012 May 1;109(9):1239-46. doi: 10.1016/j.amjcard.2011.12.015. Epub 2012 Feb 21.

PMID:
22360820
5.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators..

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

6.

Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.

Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q.

Pharmacotherapy. 2012 Sep;32(9):809-18. doi: 10.1002/j.1875-9114.2012.01112.x. Epub 2012 Jun 28.

7.

New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.

Davis EM, Packard KA, Knezevich JT, Campbell JA.

Pharmacotherapy. 2011 Oct;31(10):975-1016. doi: 10.1592/phco.31.10.975. Review.

PMID:
21950643
8.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators..

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
9.

Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.

Komócsi A, Vorobcsuk A, Kehl D, Aradi D.

Arch Intern Med. 2012 Nov 12;172(20):1537-45. doi: 10.1001/archinternmed.2012.4026. Review.

PMID:
23007264
11.

Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.

Ng FH, Tunggal P, Chu WM, Lam KF, Li A, Chan K, Lau YK, Kng C, Keung KK, Kwan A, Wong BC.

Am J Gastroenterol. 2012 Mar;107(3):389-96. doi: 10.1038/ajg.2011.385. Epub 2011 Nov 22.

PMID:
22108447
12.

Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

Kar S, Bhatt DL.

Coron Artery Dis. 2012 Sep;23(6):380-90. doi: 10.1097/MCA.0b013e328356490a. Review.

PMID:
22728913
13.

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.

White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.

Am Heart J. 2011 Oct;162(4):620-626.e1. doi: 10.1016/j.ahj.2011.08.004. Epub 2011 Sep 14.

PMID:
21982652
14.

Statins for acute coronary syndrome.

Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006870. doi: 10.1002/14651858.CD006870.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;9:CD006870.

PMID:
21678362
15.

Treatment of acute coronary syndrome: part 2: ST-segment elevation myocardial infarction.

Trost JC, Lange RA.

Crit Care Med. 2012 Jun;40(6):1939-45. doi: 10.1097/CCM.0b013e31824e18c2. Review.

PMID:
22610195
16.

Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.

Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group..

Eur Heart J. 2013 Jan;34(3):220-8. doi: 10.1093/eurheartj/ehs149. Epub 2012 Jun 19.

PMID:
22719022
17.

Management of non-ST-segment elevation acute coronary syndrome: comparison of the updated guidelines from North America and Europe.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2012 Jun;11(2):62-73. doi: 10.1097/HPC.0b013e3182563a7e. Review.

PMID:
22595816
18.

Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population.

Pollack CV Jr, Sites FD, Shofer FS, Sease KL, Hollander JE.

Acad Emerg Med. 2006 Jan;13(1):13-8. Epub 2005 Dec 19.

19.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
20.

Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.

Ahrens I, Bode C.

Future Cardiol. 2012 Jul;8(4):533-41. doi: 10.2217/fca.12.26. Review.

PMID:
22871192

Supplemental Content

Support Center